Haematological malignancies: Double act in follicular lymphoma


tested the combination of pidilizumab, a recombinant monoclonal antibody that targets PD‐1, and rituximab in patients with relapsed follicular lymphoma. The results included the analysis of 29 patients who had relapsed after one to four previous therapies and who were followed for a median of 15.4 months. The combination of pidilizumab and rituximab showed… (More)
DOI: 10.1038/nrclinonc.2014.1


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics